Romark Laboratories L.C.
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Romark Laboratories L.C. sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Romark Laboratories L.C.: 16 sponsored US clinical trials, none currently recruiting.
Romark Laboratories L.C. sponsors 16 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 10 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Clostridium Difficile, with 1 trials.
Top-decile sponsor footprint
Romark Laboratories L.C. ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (62.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
16 total, page 1 of 1
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
NCT04489381
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
NCT04486313
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
NCT04359680
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)
NCT04343248
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
NCT03605862
A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza
NCT03336619
Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
NCT02612922
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
NCT01610245
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
NCT01227421
Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza
NCT01056380
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients
NCT00637923
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C
NCT00495391
Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease
NCT00384527
Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease
NCT00130390
Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis
NCT00417872
Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients
NCT00004986
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 6 |
| Phase 3 | 10 |
Therapeutic Areas
How the Romark Laboratories L.C. archive is shaped
16 indexed studies, none listed as recruiting (0% open); 10 completed (63%).
Phase mix: 10 late (III/IV) vs 6 early (I/II) (later-stage heavy).
Top condition: Clostridium Difficile (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Romark Laboratories L.C.: archived-pipeline peers nationwide
Peers matched on 16 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Romark Laboratories L.C. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 archived trials
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Romark Laboratories L.C. page
16 registered trials is a research-attention snapshot, not an endorsement of Romark Laboratories L.C. or any single study.
- None of Romark Laboratories L.C.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Clostridium Difficile is the condition Romark Laboratories L.C. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Clostridium Difficile trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Romark Laboratories L.C. pipeline card: 16 registered trials from official public datasets.Report a data error.